Lexology March 29, 2024
DEVELOPMENT/SUPPLY/MANUFACTURING/DISTRIBUTION ISSUES[1]
The advent of the COVID-19 rapid antigen test launched at-home diagnostics to the forefront of conversation in the life sciences industry. Many believe this is only the beginning. As the share of telehealth services increases, drawing interest away from traditional healthcare services models, startups and established companies alike are positioning themselves to take advantage of the growing market for technologies and products that enable non-lab-based diagnostics capable of being purchased without a prescription and conducted entirely at home. But to minimize risk and maximize revenue, companies need to be careful in negotiating crucial provisions when contracting with third parties. MoFo’s LST+L Group provides a list of the top seven issues to consider when drafting and negotiating agreements with...
Today's Sponsors
Today's Sponsor